DENVER, CO / / December 18, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous ...
EXXUA is a novel oral selective serotonin 5HT1a receptor agonist indicated for the treatment of major depressive disorder (MDD) in adults. EXXUA is also being developed for other psychiatric disorders ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. On Monday, the Federal Reserve formally stopped shrinking its balance sheet. Analysts think it’s going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback